Waldencast Announces FDA Approval of Obagi(R) saypha(R) MagIQ(TM) Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
Waldencast Announces FDA Approval of Obagi(R) saypha(R) MagIQ(TM) Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market GlobeNewswire September 10, 2025 LONDON, Sept. 10, 2025 (GLOBE NEWSWIRE) — […]